Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...

A computational model of the more than 26 million atoms in a DNA-packed viral capsid expands our understanding of virus structure and DNA dynamics, insights that could provide new research avenues and ...

In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...

The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...